title stringlengths 1 1.19k | keywords stringlengths 0 668 | concept stringlengths 0 909 | paragraph stringlengths 0 61.8k | PMID stringlengths 10 11 |
|---|---|---|---|---|
Measures | PMC10463387 | |||
Sociodemographic variables | Demographic variables including age, gender, ethnicity, and social grade were taken using standard UK Office for National Statistics [ | PMC10463387 | ||
Analysis | self-harm | Descriptive statistics were used to summarise sociodemographic variables. Chi-square was used to compare our sample of people who reported a previous history of self-harm with general population data collected as part of the Adult Psychiatric Morbidity Survey [ | PMC10463387 | |
Results | PMC10463387 | |||
Sample characteristics | The final sample (
Sample demographics in the two groups (final sample) | PMC10463387 | ||
Randomisation check | The success of the randomisation procedure was checked using MANOVA (a flow diagram is presented in Fig.
Flow diagram showing participant allocation to each condition | PMC10463387 | ||
Baseline equivalence check | Equivalence between the participants who dropped out versus remained in the study with respect to baseline characteristics was checked using MANOVA. The independent variable was | PMC10463387 | ||
Changes in acceptability ratings over time | The proportion of participants scoring at each point on the rating scale of each item at baseline and follow-up is presented in Table
Proportion of responses at each point according to item at baseline and follow-up
Two-way repeated measures ANOVAs were used to assess the effect of the two versions of the volitional h... | PMC10463387 | ||
Discussion | This paper aimed to operationalise an approach to intervention acceptability that: (a) ensured that a large representative sample of people with lived experience is involved in the process of improving intervention acceptability; and (b) adopted a theory-driven, experimental approach to evaluating whether refining an i... | PMC10463387 | ||
Implications | Incorporating participant feedback in the design of interventions is an important stage of intervention development [ | PMC10463387 | ||
Strengths and limitations | Previous studies applying the TFA to explore intervention development have primarily been qualitative studies [Increasing acceptability is important when developing interventions iteratively, and in line with recognised guidance for intervention development. We present an experimental approach that allows researchers t... | PMC10463387 | ||
Conclusions | Incorporating participant feedback is an important consideration for the design, implementation and evaluation of interventions. The Theoretical Framework of Acceptability provides a framework designed to systematically examine the seven components associated with acceptability. Our tool provides a systematic method of... | PMC10463387 | ||
Acknowledgements | The authors wish to thank all of the participants involved in this study. | PMC10463387 | ||
Authors’ contributions | C.K. and C.J.A. conceived and designed the study. CK led the data anlysis. All authors contributed to the interpretation of the data. C.K. drafted the manuscript. All authors contributed to the manuscript edits and revisions, and approved the final version. | PMC10463387 | ||
Funding | This work was funded by the National Institute for Health and Care Research (NIHR) Greater Manchester Patient Safety Translational Research Centre (grant number: PSTRC-2016-003). C.J.A. is supported by the NIHR Manchester Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily tho... | PMC10463387 | ||
Data availability | The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request. | PMC10463387 | ||
Declarations | PMC10463387 | |||
Competing interests | The authors declare no competing interests. | PMC10463387 | ||
Ethics approval and consent to participate | Ethical approval was obtained from The University of Manchester Research Ethics Committee (ref: 2020-8446-15312). All methods were performed in accordance with the relevant guidelines and regulations (Declaration of Helsinki). All participants gave informed consent prior to the study. | PMC10463387 | ||
Consent for publication | Not applicable. | PMC10463387 | ||
References | PMC10463387 | |||
Background | osteoporosis, shock | OSTEOPOROSIS, SHOCK | This study aimed to compare the effects of high-intensity laser therapy (HILT) and extracorporeal shock wave therapy (ESWT) in treating consequences of osteoporosis in hemiparetic patients. | PMC10475189 |
Methods | hemiplegic | OSTEOPOROSIS | A randomized controlled trial was conducted on hemiplegic patients with osteoporosis. They were randomly classified into three equal groups ( | PMC10475189 |
Results | A statistically significant difference ( | PMC10475189 | ||
Keywords | Open access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB). | PMC10475189 | ||
Introduction | Stroke-related motor disability, Stroke, shock, osteoporotic, pain, fractures, Osteoporosis, osteoporosis | STROKE, SHOCK, COMPLICATIONS, POSTMENOPAUSAL OSTEOPOROSIS, OSTEOPOROSIS, OSTEOPOROSIS | Stroke is one of the most challenging medical conditions in the world. Stroke-related motor disability is leading to miscellaneous complications. Osteoporosis and consequent fractures are well known as stoke-related complications [Hemiparetic patients are predisposed to fractures due to considerable loss of bone mass o... | PMC10475189 |
Materials and methods | PMC10475189 | |||
Study design | A randomized controlled trial was carried out at the Faculty of Physical Therapy Outpatient Clinic, Cairo University, between October 2021 and March 2022. The ethical committee of the Physical Therapy Faculty at Cairo University authorized this work (No: P.T.REC/012/003393). The study was registered as a clinical trial... | PMC10475189 | ||
Participants | osteoporosis, osteopenia, hemiplegic | OSTEOPENIA, OSTEOPOROSIS | One hundred and forty hemiplegic patients with osteoporosis of both sexes were chosen randomly. Hemiparetic chronicity ranges from eight to ten years. Their age ranged from 60 to 70 years old. All participants were diagnosed by dual-energy X-ray absorptiometry (DEXA) as osteoporosis or osteopenia, where T-score was − 1... | PMC10475189 |
Exclusion criteria | RHEUMATOID ARTHRITIS, SKIN DISEASES, MUSCULOSKELETAL DISORDERS | BMI of more than 30 or less than 18, advanced musculoskeletal disorders, rheumatoid arthritis, skin diseases, long-term steroids therapy, or any drug affecting bones. | PMC10475189 | |
Randomization | osteoporosis, hemiplegic | OSTEOPOROSIS | One hundred and forty hemiplegic patients with osteoporosis were evaluated for eligibility; 12 patients disagreed to participate in this study. Therefore, one hundred and twenty-eight were randomly divided into three groups of equal size, using random allocation software (GraphPad Software Inc.) to minimize selection b... | PMC10475189 |
Outcomes measurements | Osteoporosis, pain | OSTEOPOROSIS, OSTEOPOROSIS |
Visual analog scale (VAS): a measurement tool used to evaluate patient discomfort as his/her experience to a specific degreeFall risk assessment: This was performed by two methods: Overall stability index which was obtained by (Biodex Balance Master, USA) the second method was the Short Form of Berg Balance Scale (SFB... | PMC10475189 |
Therapeutic procedures | PMC10475189 | |||
High-intensity laser therapy (HILT) | HIL was produced by ASA S.r.l.—Italy EN 60825, Nd: YAG laser, with an average power of 10.5 W and wavelength of 1064 nm. All the patients in the HIL group received three HILT sessions per week for three months. The lower back and both hips were scanned by the device by 3000 J; the average fluency was 15–10 J cm | PMC10475189 | ||
Shock wave therapy | Focused ESWT with 2000 pulses and energy of 0.12 mJ mm | PMC10475189 | ||
Power analysis | The sample size was determined using G*Power (version 3.1.9.2; Germany) [F tests-MANOVA: Repeated measures, within-between interaction], using an effect size of 0.135, a 95% power analysis, and a two-sided 5% significant level. As a result, the total estimated sample size for patients was 120 patients. | PMC10475189 | ||
Statistical analysis | The statistical analyses were calculated by SPSS version 20. The mean and SD were used to describe the study results. Paired t test was used to compare each group pre and post-intervention. ANOVA was used to compare the three groups’ clinical features and outcome measures before and after the intervention. Qualitative ... | PMC10475189 | ||
Discussion | osteonecrosis, stroke, osteoporotic, pain, Osteoporosis, femoral head osteonecrosis, osteoporosis | OSTEONECROSIS, STROKE, NON-UNION FRACTURE, OSTEOPOROSIS, NEOVASCULARIZATION, OSTEOPOROSIS | In order to assess the effectiveness of HILT and ESWT in treating osteoporotic long-term hemiparetic patients, this study was carried out. Outcome measures were visual analog scale (VAS), fall risk which was assessed using two different techniques: the overall stability index (Biodex Balance Master, USA) and the Short ... | PMC10475189 |
Conclusion | Osteoporosis | OSTEOPOROSIS | According to the current study, combining standard physical therapy with HILT and ESWT has been clinically significant in treating osteoporotic long-term hemiparetic patients, favoring HILT more than ESWT. The visual analog scale (VAS), the Short Form of Berg Balance Scale (SFBBS), and the Quality of Life Questionnaire... | PMC10475189 |
Acknowledgements | The authors express their respect and appreciation for all participants and for every contribution helped this research | PMC10475189 | ||
Author contributions | TIAE and IMAA contributed to data collection; TIAE, IMAA, and AAEMAEH were involved in formal analysis; AAEMAEH, SME, and RMMY contributed to methodology; TIAE, IMAA, and HEO were involved in writing—original draft; and AAEMAEH, SME, RMMY, and HEO contributed to review and editing. | PMC10475189 | ||
Funding | Open access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB). This research received no specific grant from any funding agency. | PMC10475189 | ||
Availability of data and materials | The data associated with the paper are not publicly available but are available from the corresponding author on reasonable request. | PMC10475189 | ||
Declarations | PMC10475189 | |||
Ethics approval and consent to participate | The current study’s methods adhered to the 1975 Helsinki Declaration’s ethical principles. The ethical committee of the Physical Therapy Faculty at Cairo University authorized this work (No: P.T.REC/012/003393). Informed consent was obtained from all subjects. All patients received a brief explanation of the examinatio... | PMC10475189 | ||
Consent for publication | Not Applicable. | PMC10475189 | ||
Competing interests | The authors declare no conflict of interest. | PMC10475189 | ||
References | PMC10475189 | |||
Supplementary Information | Comorbidity | REGRESSION | Whether patient-reported outcomes (PROs) can predict overall survival (OS) and non-relapse mortality (NRM) among recipients of allogeneic stem cell transplantation (allo-HSCT), is unclear. We performed an exploratory analysis of the prognostic value of patient-reported outcomes (PROs) among 117 recipients of allogeneic... | PMC9998318 |
Keywords | Open access funding provided by University of Oslo (incl Oslo University Hospital) | PMC9998318 | ||
Introduction | toxicity, infections, GVHD, Comorbidity | GRAFT-VERSUS-HOST DISEASE, INFECTIONS, SECONDARY, GVHD, COMPLICATIONS | Patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) have a high risk of transplant-related complications such as toxicity, infections, and graft-versus-host disease (GVHD). Approximately 50% of allo-HSCT recipients become long-term survivors [To predict mortality and transplant-related si... | PMC9998318 |
Patients and methods | PMC9998318 | |||
Approvals | The original RCT and the current study were approved by the Regional Committee for Medical and Health Research Ethics South East Norway (#S-09136c 2009/2115), and the Data Protection Supervisor, Oslo University Hospital and conducted in accordance with the Declaration of Helsinki. All patients gave written informed con... | PMC9998318 | ||
Study design and patient selection in the RCT | One hundred and seventeen patients (intervention | PMC9998318 | ||
Nutrition intervention in the original randomized controlled trial | In short, the nutritional intervention started upon hospital admission with optimization of energy and protein intake until discharge (usually after 3–5 weeks) [ | PMC9998318 | ||
Sociodemographic and clinical factors | At enrollment, all the participants provided information on the following sociodemographic factors: age, sex, education, and marital status. The electronic health records were used to provide information on disease-, transplant- and treatment-specific information such as diagnosis, conditioning regime, admission dates,... | PMC9998318 | ||
Patient-reported outcomes assessment | Cancer | CANCER | The European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire (QLQ-C30) was used to assess QoL at baseline (i.e., on day 8 or 7 before allo-HSCT) [ | PMC9998318 |
Clinical scoring systems | DISEASE | Clinical- and transplant-related data were registered daily during hospitalization and later retrieved from the medical health records. This included diagnosis and progression of disease, conditioning regime, donor information, stem cell source, the HCT-CI, and EBMT scores. The HCT-CI score summarizes the presence of 1... | PMC9998318 | |
Statistical analyses | REGRESSION | All descriptive statistics were performed and reported overall and by study group affiliation (intervention and control). Due to the exploratory nature of the current study, we assessed all the scales from the QLQ-C30 questionnaire without selecting any primary scales. For each scale, we used Cox proportional hazard mo... | PMC9998318 | |
Results | PMC9998318 | |||
Patient inclusion | In the original RCT, 173 patients ≥ 18 years of age undergoing allo-HSCT with myeloablative conditioning were assessed for eligibility. Of these, 119 patients consented and were randomly assigned to receive the nutrition intervention or the standard total parental nutrition. Two patients in the intervention group were ... | PMC9998318 | ||
Univariable analyses for 1-year non-relapse mortality | Univariable analysis on the prognostic significance of the clinical-sociodemographic variables are shown in Supplementary Table | PMC9998318 | ||
Discussion | appetite loss, GVHD | APPETITE LOSS, GVHD, COMPLICATIONS, COMPLICATION | Our findings suggest that both the HCT-CI- and the EBMT scores at baseline were prognostic for 1-year OS and for 1-year NRM. None of the PROs from the EORTC QLQ C30 questionnaire remained significant in the multivariable analysis on 1-year OS. Moreover, the analyses suggested that only appetite loss, living alone, and ... | PMC9998318 |
Acknowledgements | The authors would like to thank all the patients and their families for participating in this study. | PMC9998318 | ||
Author contribution | POI | AMG, KJS, MJH, GET, FE, FC, and POI designed this study, analyzed the data, and drafted the manuscript. FE and FC performed the statistical analysis and contributed to the data analysis and data interpretation. All authors critically reviewed the manuscript and approved the final version. The corresponding author had f... | PMC9998318 | |
Funding | Open access funding provided by University of Oslo (incl Oslo University Hospital) The study was supported by Oslo University Hospital, Helse Sør-Øst Trust and the Throne Holst Foundation. | PMC9998318 | ||
Data availability | The data that supports the findings of this study are available from the corresponding author on reasonable request. | PMC9998318 | ||
Declarations | PMC9998318 | |||
Competing interests | FE: had a consultancy or advisory role for AbbVie, Incyte, Janssen, and Syros, outside the submitted work. GET: research grants from Mundipharma and Alexion Pharmaceuticals, advisory board honoraria from Alexion Pharmaceuticals and Janssen-Cilag, and lecture honoraria from Novartis, Janssen-Cilag, Alexion Pharmaceutica... | PMC9998318 | ||
References | PMC9998318 | |||
Introduction | agoraphobia, agoraphobic, Agoraphobia, anxiety, Anxiety, panic disorder, Panic disorder, panic, F41.0, depression, anxiety-related disorders | DISORDER, EVENT, DISEASE, DISORDERS | The Global Burden of Disease (GBD) estimated that the COVID-19 pandemic has led to a 25.6% increase (95% uncertainty interval (UI): 23.2–28.0) in cases of anxiety disorders worldwide in 2020 [Panic disorder is an anxiety disorder characterized by reoccurring unexpected panic attacks. Agoraphobia refers to avoidance or ... | PMC10313059 |
Methods | PMC10313059 | |||
Original study design | panic disorder, agoraphobia, Anxiety | The aim of the PARADIES cluster randomized trial (cRCT; conducted between 2012 and 2016) was to deliver a low intensity and effective therapy to people with panic disorder with or without agoraphobia in a primary care setting. This cRCT in 73 GPs’ practices included 419 patients with panic disorder with or without agor... | PMC10313059 | |
Present study sample | MAY | For the 60 months follow-up, all patients (N = 419) of the original PARADIES cRCT (conducted between 2012 and 2016) were contacted repeatedly in various ways (telephone, letter, email) from October 2020 to May 2021. The follow-up was completed by 56/230 (24%) patients from 27/36 practices in the IG and 44/189 (23%) pat... | PMC10313059 | |
Flow chart. | PMC10313059 | |||
Characteristics of patients. | *Patients’ characteristics of the original study see supplement and original publication [ | PMC10313059 | ||
Clinical outcomes | Anxiety, anxiety | The severity of anxiety was assessed with the Beck Anxiety Inventory (BAI) [ | PMC10313059 | |
Statistical analysis | PMC10313059 | |||
A. Cross sectional analysis of the primary and secondary outcome variables at 60 months follow-up | Descriptive analyses of the impact of the intervention on the outcome variables BAI, OASIS, MIA, PHQ-9, PAS A1, PAS A2, fear-of-COVID-19-scale and PACIC were performed with at t-test for independent samples; a p-value smaller than 0.05 meant statistical significance. | PMC10313059 | ||
B. Longitudinal analysis: Comparison at baseline, 6 months follow-up and 60 months follow-up | For the comparison of three different measurement dates TAll statistical analyses were carried out with IBM SPSS Statistics, version 28.0. | PMC10313059 | ||
Results | PMC10313059 | |||
Cross sectional comparison at 60 months follow-up of mean sum scores in anxiety and depression symptoms. | Anxiety, Panic, Agoraphobia, anxiety, panic, depression | CHRONIC ILLNESS | BAI, Beck Anxiety Inventory; MIA, Mobility Inventory, subscale alone; OASIS, Overall Anxiety and Impairment Scale; PACIC, Patient Assessment of Chronic Illness Care; PHQ-9, Patient Health Questionnaire; PAS, Panic and Agoraphobia Scale; SD, Standard deviation* Missing data: BAI—4 patients from IG, 2 patients from CG; O... | PMC10313059 |
B. Longitudinal analysis: Comparison at baseline, 6 months follow-up and 60 months follow-up | PMC10313059 | |||
B1. Anxiety symptoms (BAI) | anxiety | The KST (p > .05) indicated equal distributions for IG (n = 34) and CG (n = 22). There was a statistically significant difference in median BAI anxiety symptoms at T | PMC10313059 | |
Comparison of IG and CG boxplots of median BAI score at different time points (T0, T1, T | PMC10313059 | |||
B2. Depression symptoms (PHQ-9) | The KST ( | PMC10313059 | ||
Comparison of IG and CG boxplots of median BAI score at different time points (T0, T1, T | PMC10313059 | |||
B3. Frequency of panic attacks (PAS) | ( | PMC10313059 | ||
B4. Intensity of panic attacks (PAS) | The KST ( | PMC10313059 | ||
B5. Patient Assessment of Chronic Illness Care (PACIC) | The KST ( | PMC10313059 | ||
Discussion | agoraphobic, panic disorders, anxiety, panic disorder, panic, anxiety-related impairments, depression | VIRUS | More than five years after the original trial ended, we investigated potential long-term effects of a practice team-based intervention (CBT and case management) for patients with panic disorder during the Covid-19 pandemic. Group differences of the anxiety severity (OASIS) in cross sectional analysis at the 60months fo... | PMC10313059 |
Strength and limitations | depression, anxiety | The strength of the present analysis is its thorough assessment of anxiety and depression outcomes during a natural crisis situation. A limitation of the study is the low response rate. Although we tried several ways to contact participants, we could only include participants who were accessible and willing to particip... | PMC10313059 | |
Conclusion | agoraphobia, Fuchs, anxiety, panic disorder, PD, depression | SALZMANN, FUCHS, SCHMIDT | A practice team-based intervention (CBT and case management) for primary care patients with panic disorder with or without agoraphobia may have had a lasting impact regarding anxiety severity despite the challenging context of the Covid-19 pandemic. CBT strategies which patients can apply on their own after termination... | PMC10313059 |
References | PMC10313059 | |||
Background | cancer, helplessness/hopelessness, anxiety | CANCER | These authors contributed equally to this work.While shared decision making (SDM) is advocated for ethical reasons and beneficial outcomes, SDM might also negatively affect patients with incurable cancer. The current study explored whether SDM, and an oncologist training in SDM, are associated with adverse outcomes (i.... | PMC10712204 |
Design | SECONDARY, ADVANCED CANCER, REGRESSIONS | A secondary analysis of a randomized clinical trial investigating the effects of SDM interventions in the context of advanced cancer. The relations between observed SDM (OPTION12), specific SDM elements (4SDM), oncologist SDM training, and adverse outcomes were analyzed. We modeled adverse outcomes as a multivariate ph... | PMC10712204 | |
Results | In total, 194 patients consulted by 31 oncologists were included. In a multivariate analysis, observed SDM and adverse outcomes were significantly related. More specifically, more observed SDM in the consultation was related to patients reporting more tension ( | PMC10712204 | ||
Conclusions | It is important for oncologists to realize that for some patients, SDM may temporarily be associated with negative emotions. Further research is needed to untangle which, when, and how adverse outcomes might occur and whether and how burden may be minimized for patients. | PMC10712204 | ||
Highlights | cancer, anxiety | CANCER, ADVANCED CANCER | Observed shared decision making was related to more tension and uncertainty postconsultation in advanced cancer patientsHowever, training oncologists in SDM did not affect adverse outcomes.Further research is needed to untangle which, when, and how adverse outcomes might occur and how burden may be minimizedPatients wi... | PMC10712204 |
Methods | PMC10712204 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.